Boston Trust Walden Corp Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
MarketBeat
Boston Trust Walden Corp lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 866,872 shares of the biopharmaceutical company's stock after selling 7,209
NASDAQ:HALO